Mark Schmidt MD, BA

Schmidt is a Senior Director in Experimental Medicine for Janssen Pharmaceutica in Beerse, Belgium. He received his medical degree from the University of Chicago in 1983 and entered postgraduate training in psychiatry in the US Navy. Dr. Schmidt was a research fellow in the National Institute of Mental Health (NIMH) where he focused on the use of functional imaging as a pharmacodynamic marker. Following fellowship, he worked at Lilly, Novartis, and now Janssen. He is responsible for clinical testing of NMEs for psychiatric indications through proof of concept, and has led a preclinical imaging group for development of site specific PET tracers and then qualifying them in human. He has authored over 75 peer-reviewed manuscripts, reviews, and book chapters, many on the use of imaging for CNS drug development.